首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNL3 |
| Uniprot No | Q8IZI9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-196aa |
| 氨基酸序列 | VPVARLRGA LPDARGCHIA QFKSLSPQEL QAFKRAKDAL EESLLLKDCK CRSRLFPRTW DLRQLQVRER PVALEAELAL TLKVLEATAD TDPALGDVLD QPLHTLHHIL SQLRACIQPQ PTAGPRTRGR LHHWLHRLQE APKKESPGCL EASVTFNLFR LLTRDLNCVA SGDLCV |
| 预测分子量 | 21,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IFNL3重组蛋白的参考文献概览：
---
1. **文献名称**: *Production of recombinant human interferon lambda 3 and its protective effect against hepatitis C virus infection*
**作者**: Li, J., et al.
**摘要**: 研究报道了通过大肠杆菌系统高效表达IFNL3重组蛋白的优化方法，并证实其体外显著抑制HCV病毒复制，机制与激活JAK-STAT通路相关。
2. **文献名称**: *Structural and functional characterization of interferon lambda 3 homologs in mammalian species*
**作者**: Prokunina-Olsson, L., et al.
**摘要**: 通过对比不同物种IFNL3重组蛋白的结构与功能，揭示了其受体结合区域的关键氨基酸残基，为设计靶向IFNLR1受体的治疗分子提供依据。
3. **文献名称**: *Recombinant IFN-λ3 (IL-28B) inhibits Zika virus replication in human corneal epithelial cells*
**作者**: Zhang, Y., et al.
**摘要**: 研究利用HEK293细胞表达IFNL3重组蛋白，证明其通过诱导ISGs(干扰素刺激基因)抑制寨卡病毒在人角膜细胞中的感染，提示其抗RNA病毒广谱潜力。
---
**注**：以上文献为示例，实际引用需核对具体论文信息。建议通过PubMed或Web of Science以关键词“IFNL3 recombinant”或“interferon lambda 3 expression”获取最新研究。
Interferon Lambda 3 (IFNL3), also known as interleukin-28B (IL-28B), is a cytokine belonging to the type III interferon (IFN-λ) family, which includes IFNL1. IFNL2. IFNL3. and IFNL4. These cytokines share structural and functional similarities with type I interferons but signal through a distinct receptor complex composed of IFNLR1 and IL10Rβ. IFNL3 is primarily produced by immune cells and epithelial tissues in response to viral infections, playing a critical role in innate antiviral defense. It activates the JAK-STAT signaling pathway, inducing the expression of interferon-stimulated genes (ISGs) that inhibit viral replication and modulate immune responses.
The therapeutic potential of IFNL3 gained prominence due to its association with genetic polymorphisms, particularly the rs12979860 single nucleotide polymorphism (SNP), which strongly influences clinical outcomes in hepatitis C virus (HCV) infection. Individuals with favorable IFNL3 genotypes exhibit enhanced viral clearance and better responses to pegylated interferon-α-based therapies. This discovery spurred interest in recombinant IFNL3 protein as a targeted therapeutic agent.
Recombinant IFNL3 is produced using genetic engineering techniques, often in bacterial or mammalian expression systems, to ensure proper folding and bioactivity. Preclinical studies highlight its antiviral efficacy against HCV, hepatitis B virus (HBV), and other viruses, with potential advantages over type I IFNs, such as reduced systemic toxicity due to restricted receptor distribution. Additionally, IFNL3’s immunomodulatory properties are being explored in cancer immunotherapy and inflammatory diseases.
Recent research also investigates its role in COVID-19. as IFNL3 may mitigate SARS-CoV-2 replication while modulating hyperinflammatory responses. Despite promising preclinical data, clinical translation faces challenges, including optimizing delivery methods and understanding tissue-specific effects. Overall, recombinant IFNL3 represents a promising candidate for antiviral and immunotherapeutic applications, bridging innate immunity and precision medicine.
×
